|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||4.73 / 18.93|
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
Brendan Delaney Named Chief Commercial Officer
Investors in Immunomedics, Inc. saw new options become available this week, for the December 15th expiration.
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 4,840,764 share decrease in total short interest for Immunomedics, Inc. , to 29,775,931, a decrease of 13.98% since 09/15/2017.
The key to dealing with this environment is to keep an open mind.
Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology
Obtains stockholder approval to increase authorized capital stock
Investors eyeing a purchase of Immunomedics, Inc. shares, but tentative about paying the going market price of $7.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.
Closes on $125 million private placement financing with institutional investors
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.